Clinical Trial Update: Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Fluzopalil in combination with Anlotinib for extensive small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Fluzopalil

Snippet

Sponsor: Liu Zhenhua | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN